ClinicalTrials.gg
Not yet recruitingNCT06547333Updated Aug 14, 2024

A Study of CM310 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease

A Phase 2/3 interventional study of CM310 and Placebo in Chronic Obstructive Pulmonary Disease, sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd.. Not yet recruiting. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-08-14.

Sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
884
Allocation
Randomized
Ages
40 Years to 85 Years
Sex
All
01

Study summary

This study is a multi-center, randomized, double-blind, placebo-controlled Phase Ⅱ/Ⅲ clinical study to evaluate the efficacy, safety, PK characteristics, PD effects and immunogenicity of CM310 in subjects with moderate to severe Chronic Obstructive Pulmonary Disease(COPD).

The study has two parts. Each part consists of three periods, including an up to 4-week screening period, a 52-week randomized treatment period, and a 8-week safety follow-up period.

Read the detailed description

The study has two parts. Each part consists of three periods, including an up to 4-week screening period, a 52-week randomized treatment period, and a 8-week safety follow-up period. During the first part, patients who meet eligibility criteria will be randomized 1:1:1 to receive either CM310 300 mg, CM310 150mg or matched placebo subcutaneously every two weeks (Q2W) for a total of 26 times at the double-blind treatment period. An interim analysis will be performed and an optimal dose will be recommended. During the second part, patients will be randomized 1:1 to receive either CM310 optimal dose or matched placebo subcutaneously at the double-blind treatment period.

02

Conditions studied

  • Chronic Obstructive Pulmonary Disease
03

In context

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

This study's planned enrollment of 884 is above the median of 62 across 3,841 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.

Browse Pulmonary Disease, Chronic Obstructive studies →

Lead sponsor

CSPC ZhongQi Pharmaceutical Technology Co., Ltd. is the lead sponsor of 167 studies on the registry; 47 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have the ability to understand the nature of the study and voluntarily sign the form.
  2. Age ≥40 and ≤85 years old, male or female, at the time of signing the informed consent.
  3. The patient has been diagnosed with for at least 1 year, and meet the following criteria at screening.

    1. Moderate to severe COPD (post-bronchodilator /FVC ratio \<0.70 and post-bronchodilator FEV1 % predicted >30% and ≤70%) at screening.
    2. Modified Medical Research Council (mMRC) Dyspnea Scale grade ≥2.
    3. Signs and symptoms (chronic productive cough) of chronic bronchitis for at least 3 months in the year up to screening and in the absence of other known causes of chronic cough.
    4. Documented history of high exacerbation risk defined as exacerbation history of ≥2 moderate or ≥1 severe AECOPD within the year prior to screening. At least one exacerbation should have occurred while the patient was taking inhaled (ICS)/long acting beta agonist (LABA)/long acting muscarinic antagonist (LAMA) (or LABA/LAMA if ICS is ). Moderate acute exacerbation of COPD (AECOPD) aredefined as exacerbations that require either systemic corticosteroids (intramuscular, intravenous, or oral) and/or antibiotics. One of the two required moderate exacerbations has to require the use of systemic corticosteroids. Severe AECOPD are defined as exacerbations requiring hospitalization or observation >24 hours in emergency department/urgent care facility.
    5. Background triple therapy (ICS + LABA + LAMA) for 3 months prior to screening with a stable dose of medication for ≥1 month prior to screening; Double therapy (LABA + LAMA) allowed if ICS is contraindicated.
    6. Evidence of Type 2 inflammation: Patients with blood eosinophils ≥0.3×10\^9 /L at Visit 1.
  4. (BMI) ≥16 kg/m\^2
  5. Participants (including partners) have no plans to have children and voluntarily used highly effective within 3 months after the last dose of study drug from the date of signing the informed consent.

Exclusion criteria

Exclusion Criteria:

  1. A current diagnosis of asthma or history of asthma according to the Global Initiative for Asthma (GINA) guidelines or other accepted guidelines(asthma alone or asthma as the primary diagnosis, including but not limited to asthma with ).
  2. Subjects with significant pulmonary disease other than COPD (e.g., sarcoidosis, interstitial lung disease, primary pulmonary hypertension, bronchiectasis, Churg-Strauss Syndrome, active tuberculosis or non-tuberculous mycobacterial infection, etc.), in the opinion of the investigator.
  3. Subjects with other conditions that could lead to elevated eosinophils such as hypereosinophilic syndromes, eosinophilic granulomatosis with polyangiitis (EGPA), eosinophilic esophagitis or other disease(e.g., active parasitic infection (helminthes) which has not been treated with, or has failed to respond to standard of care therapy.)
  4. Heart failure Class IV, uncontrolled Cor pulmonale as judged by the Investigator or with evidence of right cardiac failure.
  5. Treatment with oxygen of more than 15 hours per day or hypercapnia requiring BiPAP, in the opinion of the investigator,
  6. Acute moderate or severe exacerbation of COPD (AECOPD, as defined above in Inclusion Criteria) from 4 weeks before signing consent to the time of randomization.
  7. Acute infection requiring systemic anti-infective therapy from 4 weeks before signing consent to the time of randomization.
  8. History of or planned pneumonectomy or lung volume reduction surgery for COPD. Patients who are participating in the acute phase of a pulmonary rehabilitation program, ie, who start rehabilitation \<4 weeks prior to screening (Note: patients in the maintenance phase of a rehabilitation program could be included).
  9. Diagnosis of α-1 anti-trypsin deficiency.
  10. Anti-immunoglobulin E (IgE) therapy (omalizumab) within 130 days before consent or any other biologic therapy (including other anti-IL4R mAb, anti-IL5 mAb, anti-IL5R mAb, anti TSLP mAb, anti-IL33 mAb, anti-ST2 mAb) within 3 months or 5 half-lives before signing consent, whichever is longer.
  11. Prior disease (eg, rheumatoid arthritis, inflammatory bowel disease, primary biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis, etc) or inflammatory treatment with biologic agents/systemic agents (including but not limited to methotrexate, cyclosporine, mycophenolate mofetil, tacrolimus, penicillamine, sulfasalazine, hydroxychloroquine, azathioprine, cyclophosphamide) within 8 weeks or 5 half-life periods (whichever is longer) prior to consent.
  12. Receipt of immune globulin or blood products within 30 days before consent.
  13. Patients who are treated with systemic (topical, ophthalmic, or intranasal corticosteroids are excluded) from 4 weeks before signing the to the date of randomization. Except for short-term (≤7 days) use of systemic glucocorticoids to prevent or treat non-autoimmune allergic diseases.
  14. Use of macrolide antibiotics (eg, azithromycin) unless stable >3 months prior to screening visit and maintain the treatment during the planned study period.
  15. Receipt of live or attenuated vaccine within 3 months before consent signing or during the planned study period
  16. Previous history of known or suspected immunosuppression, including a history of invasive opportunistic infection (eg, histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, aspergillosis), even if the infection has resolved; Or the presence of unusual frequent, recurrent, or prolonged infections, per investigator's judgment.
  17. History of : subjects with basal cell carcinoma, localized squamous cell carcinoma of the skin, or carcinoma in situ of the cervix are eligible to enter the study if they have completed curative treatment for at least 12 months before signing the informed consent. Subjects with other malignancies are allowed to enter the study if they have completed curative treatment for at least 5 years before signing the informed consent.
  18. The presence of any severe and/or uncontrolled medical condition that in the judgment of the investigator would affect the evaluation of the drug, including but not limited to: severe neurological disease (eg, epilepsy, dementia, etc), history of severe mental disorder, major cardiovascular disease, diabetes mellitus poorly controlled by intensive treatment, interval prolongation(male >450 msec, female >470 msec), or persistent arrhythmia.
  19. Positive screening serologic test for or treponema pallidum during screening.
  20. Chronic virus or virus infection meets the criteria:

    • HBsAg positive;
    • If HBsAg is negative and HBcAb is positive, HBV DNA should be tested (test result ≥1000 IU/mL).
    • If the test is positive for HCV antibody, HCV RNA is added (with a result above the at the participating center).
  21. Subjects with abnormal liver and kidney function, such as or alanine aminotransferase >3 times the upper limit of normal, or serum creatinine>1.5 times the upper limit of normal.
  22. Acute myocardial infarction \<6 months from screening visit.
  23. Stroke \< 6 months from screening visit.
  24. Cardiac arrhythmias including paroxysmal (eg, intermittent) atrial fibrillation are excluded. Patients with persistent atrial fibrillation as defined by continuous atrial fibrillation for at least 6 months and controlled with a rate control strategy (ie, selective beta blocker, calcium channel blocker, pacemaker placement, digoxin or ablation therapy) and stable appropriate level of anticoagulation for at least 6 months may be considered for inclusion.
  25. Unstable ischemic heart disease or other relevant cardiovascular disorder such as pulmonary embolism, deep vein thrombosis within ≤6 months from screening visit that in investigator's judgment may put the patient at risk or negatively affect the study outcome.
  26. Major surgery within 8 weeks prior to consent or planned surgery requiring general anesthesia or hospitalization for > 1 day during the study period.
  27. Fertile women with positive pregnancy test results during screening; Pregnant or lactating women.
  28. Allergy or intolerance to components of CM310 injection or placebo or history of severe drug allergy or anaphylactic shock.
  29. Exposure to another investigative drug (small molecules as well as monoclonal antibodies) within a time period prior to consent signing that is less than 6 months. The minimum interval since exposure to any other (non-antibody) investigative study medication is 30 days prior to signing consent.
  30. History of drug abuse within 5 years before signing informed consent.
  31. Background medication treatment compliance \< 70%
  32. Investigators and associated site personnel or others directly involved in the implementation of the protocol.
  33. The investigator considers that there are any conditions that may prevent the subject from completing the study or present a significant risk to the subject or other factors that may reduce the likelihood of enrolment.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
884 participants (estimated)

Study arms

  • Experimental
    CM310 300mg Q2W

    CM310 is injected subcutaneously (SC) 300 mg each time, once every 2 weeks (Q2W) for a total of 26 doses.

    Drug: CM310

  • Experimental
    CM310 150mg Q2W

    CM310 is injected subcutaneously (SC) 150 mg each time, once every 2 weeks (Q2W) for a total of 26 doses.

    Drug: CM310

  • Placebo comparator
    Placebo

    Subcutaneous injection (SC), once every 2 weeks (Q2W) for a total of 26 doses.

    Drug: Placebo

Interventions

  • DrugCM310

    CM310 Recombinant Humanized Monoclonal Antibody Injection

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Annualized Rate of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Acute Exacerbations

    Moderate acute exacerbation of COPD (AECOPD) are defined as exacerbations that require either systemic corticosteroids (intramuscular, intravenous, or oral) and/or antibiotics. Severe AECOPD are defined as exacerbations requiring hospitalization or observation \>24 hours in emergency department/urgent care facility. For both moderate and severe events to be counted as separate events, they are separated by at least 14 days. Annualized event rate are the total number of exacerbations that occure during the treatment period divided by the total number of participant-years treated.

    Time frame: Baseline (Day 1) to 52 weeks

Secondary outcomes

  1. Time to First Moderate or Severe Acute Exacerbation of COPD (AECOPD)

    The time to first moderate or severe exacerbation is defined as date of the first event minus randomization date +1. The median time to first severe exacerbation is derived from Cox regression model.

    Time frame: Baseline (Day 1) to 52 weeks

  2. Annualized Rate of Severe Acute Exacerbations of COPD

    Severe AECOPD are defined as exacerbations requiring hospitalization or observation \>24 hours in emergency department/urgent care facility. For severe events to be counted as separate events, they are separated by at least 14 days. Annualized event rate are the total number of exacerbations that occure during the treatment period divided by the total number of participant-years treated.

    Time frame: Baseline (Day 1) to 52 weeks

  3. Change from baseline in pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at week 12

    The FEV1 is the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometer. Spirometry is performed after a wash out period of bronchodilators according to their action duration.

    Time frame: Baseline (Day 1) to 12 weeks

  4. Change from baseline in pre-bronchodilator FEV1 at week 52

    The FEV1 is the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometer. Spirometry is performed after a wash out period of bronchodilators according to their action duration.

    Time frame: Baseline (Day 1) to 52 weeks

  5. Change from baseline in pre-bronchodilator FEV1 at week 2,4,8,16,20,24,28,36,44,48

    The FEV1 is the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometer. Spirometry is performed after a wash out period of bronchodilators according to their action duration.

    Time frame: Baseline (Day 1) to week 2,4,8,16,20,24,28,36,44,48

  6. Change from baseline in post-bronchodilator FEV1 at week 2,4,8,12,24,36,52

    The FEV1 is the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometer. Post-BD FEV1 refers to the spirometry performed within 15-30 minutes after administration of bronchodilator.

    Time frame: Baseline (Day 1) to week 2,4,8,12,24,36,52weeks

  7. Change from baseline in Forced vital capacity(FVC)and forced expiratory flow (FEF) at 25%-75% at week 2,4,8,12,16,24,28,36,44,52

    FVC is defined as the volume of air (in liters) that can be forcibly blown out after full inspiration in the upright position. FEF is the amount of air (in liters) which can be forcibly exhaled from the lungs in the first second of a forced exhalation. FEF 25-75% is defined as the mean FEF between 25% and 75% of the FVC. Spirometry is performed after a wash out period of bronchodilators according to their action duration.

    Time frame: Baseline (Day 1) to week 2,4,8,12,16,24,28,36,44,52weeks

  8. Change from baseline in Saint (St.) George's Respiratory Questionnaire (SGRQ) Total Score at week 52

    The SGRQ is a 50-item self-administered questionnaire designed to measure and quantify health status in adult participants with chronic airflow limitation and rate on electronic diary. Scores by dimension are calculated for 3 domains: symptoms, activity and impacts (psycho-social) as well as a total score. Global and domain scores range from 0 to 100, with 100 representing the worst possible health status and 0 indicating the best possible health status. Higher score indicates worse health status/heath related quality of life.

    Time frame: Baseline (Day 1) to 52 weeks

  9. Percentage of Participants With SGRQ Improvement >=4 Points from baseline at Week 52

    A responder is defined as a participant with improvement from baseline in SGRQ total score at Week 52 by \>=4 points. Participants with improvement \<4 points or with missing values are considered as non-responders. The percentage of participants who achieved a clinically meaningful response in SGRQ total score (reduction \[improvement\] by \>=4 points)/responders are reported.

    Time frame: Baseline (Day 1) to 52 weeks

  10. Change from baseline in COPD assessment test (CAT) Total Score at each evaluation time point

    The COPD Assessment Test is a validated, short and simple patient completed questionnaire to measure the health status of patients with COPD. The CAT is an 8-item questionnaire suitable for completion by all patients diagnosed with COPD. When completing the questionnaire, subjects rate their experience on a 6-point scale, ranging from 0 (no impairment) to 5 (maximum impairment) with a scoring range of 0-40. Higher scores indicate greater disease impact.

    Time frame: Baseline (Day 1) to week 2,4,8,12,24,36,44,52weeks

  11. Percentage of Participants With CAT Improvement >=2 Points from baseline at Week 52

    A responder is defined as a participant with improvement from baseline in CAT total score at Week 52 by \>=2 points. Participants with improvement \<2 points or with missing values are considered as non-responders. The percentage of participants who achieved a clinically meaningful response in CAT total score (reduction \[improvement\] by \>=2points)/responders are reported.

    Time frame: Baseline (Day 1) to 52 weeks

  12. Change from baseline in Evaluating Respiratory Symptoms (E-RS) total score at each evaluation time point

    The E-RS in COPD scale is a derivative instrument used to measure the effect of treatment on the severity of respiratory symptoms in stable COPD. E-RS: COPD RS-Total Score is derived based on weekly averages of daily assessed 11 respiratory symptom items contained in the 14-item EXACT questionnaire. The RS-Total score represent overall respiratory symptom severity, ranged from 0 to 40. The higher the score, more severe are the symptoms.

    Time frame: Baseline (Day 1) to week 2,4,8,12,24,36,44,52weeks

  13. Percentage of Participants With E-RS Improvement >=2 Points from baseline at Week 52

    A responder is defined as a participant with improvement from baseline in E-RS total score at Week 52 by \>=2 points. Participants with improvement \<2 points or with missing values are considered as non-responders. The percentage of participants who achieved a clinically meaningful response in E-RS total score (reduction \[improvement\] by \>=2points)/responders are reported.

    Time frame: Baseline (Day 1) to 52 weeks

  14. Incidence of Adverse events (AEs)/treatment-emergent adverse events (TEAEs)

    An Adverse Event (AE) is defined as any untoward medical occurrence in a participant temporally associated with the use of study treatment, whether or not considered related to the study treatment. TEAEs are defined as AEs that developed or worsened in grade or became serious during TE period which is defined as the period from the time of first dose of study treatment until the last visit in the study.

    Time frame: Baseline (Day 1) to 60 weeks

  15. Potentially clinically significant laboratory abnormalities in hematology, biochemistry and urinalysis

    Any abnormal laboratory test results (hematology, biochemistry, or urinalysis) including those that worsen from baseline, and felt to be clinically significant in the medical and scientific judgment of the investigator are to be recorded.

    Time frame: Baseline (Day 1) to 60 weeks

  16. Trough concentration at steady-state of CM310 (Pharmacokinetic parameters)

    To evaluate the trough concentration at steady-state of CM310 for each dose group. Population pharmacokinetic analysis is performed.

    Time frame: Baseline (Day 1) to 60 weeks

  17. Total IgE(Pharmacodynamic biomarkers)

    Change from baseline in total IgE at each evaluation time point for each dose group.

    Time frame: Baseline (Day 1) to 60 weeks

  18. Fractional exhaled nitric oxide (Pharmacodynamic biomarkers)

    FeNO is a demonstrated biomarker of type 2 airway inflammation in respiratory diseases. This assessment is conducted prior to spirometry. Change from baseline in FeNO at each evaluation time point for each dose group is measured.

    Time frame: Baseline (Day 1) to 60 weeks

  19. Anti-drug antibodies(immunogenicity parameters)

    Incidence of anti-drug antibodies (ADAs)

    Time frame: Baseline (Day 1) to 60 weeks

  20. Neutralizing antibodies(immunogenicity parameters)

    Incidence of neutralizing antibodies (Nabs) (if applicable)

    Time frame: Baseline (Day 1) to 60 weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2024; primary completion for Apr 2032, 91 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2024
First posted
Aug 9, 2024
StartEst.
Sep 13, 2024
Primary completionEst.
Apr 29, 2032
CompletionEst.
Oct 31, 2032
Last update
Aug 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06547333
Responsible party
Sponsor
First posted
Aug 9, 2024
Start date
Sep 13, 2024 (estimated)
Primary completion
Apr 29, 2032 (estimated)
Completion
Oct 31, 2032 (estimated)
Last update
Aug 14, 2024

Study contacts

Clinical Trials Information Group officer
Contact
ctr-contact@cspc.cn
86-0311-69085587

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Stapokibart

Start the discussion